

Anti-TNFRSF4/OX40/CD134 Antibody (Tavolixizumab)

Introduction

Tavolixizumab (MEDI 0562; Tivolimab) is a humanized TNFRSF4 (TNF receptor superfamily member 4) monoclonal antibody for cancer immunology research.

Product parameters

Alternative Names	MEDI0562, MEDI-0562, tivolimab
Target Accession	P43489
Target	TNFRSF4 / OX40 / CD134
CAS number	1635395-25-3
Molecular Weight	146.36 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CD134 His at 2 ug/mL can bind Anti-TNFRSF4/OX40/CD134 Antibody (Tavolixizumab), EC50=0.03236 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

